RwHealth secures £6.2m in Series A funding led by Maven VC to advance healthcare analytics.
The Series A round was led by Maven VC and Guinness Asset Management to support post-pandemic healthcare recovery.
RwHealth is an artificial intelligence healthcare partner providing a data science platform that helps hospitals anticipate demand and combat bed shortages. The company works with over forty providers in the UK and internationally to improve patient outcomes and clinical efficiency.
RwHealth has secured £6.2m in Series A funding to support healthcare partners with artificial intelligence post-pandemic. The investment round was led by Maven VC alongside Guinness Asset Management and ICON Corporate Finance. The fresh capital will be deployed to assist clinicians in managing elective recovery backlogs within the NHS and to advance clinical research for complex diseases.
The firm has experienced strong commercial traction, reporting 160 per cent year-on-year growth and working with more than forty providers across the UK, the Middle East, and Australia. Its technology has processed millions of patient records to help hospitals tackle waiting list issues and bed shortages exacerbated by the health crisis.
From the founder
"As we continue to accelerate and invest in the ethical use of clinical research data to advance new medicines for patient care, this funding gives us the capital needed to carry out our immediate plans while delivering AI solutions which will help futureproof our NHS."
Orlando Agrippa
CEO and Founder at RwHealth
Investor perspective
"RwHealth is at the forefront of the drive to use real world evidence and predictive analytics more effectively in the healthcare and pharma sectors – ultimately, this will enable better patient outcomes and will be more vital than ever in the post pandemic era. The company has seen significant commercial growth through its blue-chip customer base which includes NHS Trusts and large pharma companies and is now poised to scale up internationally. We are delighted to be able to support the company’s next phase of growth through this investment via a number of our funds and co-investment partners."
Alexander Sleigh
Investment Director, Maven
